924 related articles for article (PubMed ID: 19671877)
1. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.
Weber J; Thompson JA; Hamid O; Minor D; Amin A; Ron I; Ridolfi R; Assi H; Maraveyas A; Berman D; Siegel J; O'Day SJ
Clin Cancer Res; 2009 Sep; 15(17):5591-8. PubMed ID: 19671877
[TBL] [Abstract][Full Text] [Related]
2. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial.
Thompson JA; Hamid O; Minor D; Amin A; Ron IG; Ridolfi R; Assi H; Berman D; Siegel J; Weber JS
J Immunother; 2012 Jan; 35(1):73-7. PubMed ID: 22130164
[TBL] [Abstract][Full Text] [Related]
3. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
Weber JS; Gibney G; Sullivan RJ; Sosman JA; Slingluff CL; Lawrence DP; Logan TF; Schuchter LM; Nair S; Fecher L; Buchbinder EI; Berghorn E; Ruisi M; Kong G; Jiang J; Horak C; Hodi FS
Lancet Oncol; 2016 Jul; 17(7):943-955. PubMed ID: 27269740
[TBL] [Abstract][Full Text] [Related]
4. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.
Berman D; Parker SM; Siegel J; Chasalow SD; Weber J; Galbraith S; Targan SR; Wang HL
Cancer Immun; 2010 Nov; 10():11. PubMed ID: 21090563
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
Di Giacomo AM; Ascierto PA; Pilla L; Santinami M; Ferrucci PF; Giannarelli D; Marasco A; Rivoltini L; Simeone E; Nicoletti SV; Fonsatti E; Annesi D; Queirolo P; Testori A; Ridolfi R; Parmiani G; Maio M
Lancet Oncol; 2012 Sep; 13(9):879-86. PubMed ID: 22894884
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab-induced colitis in patients with metastatic melanoma.
De Felice KM; Gupta A; Rakshit S; Khanna S; Kottschade LA; Finnes HD; Papadakis KA; Loftus EV; Raffals LE; Markovic SN
Melanoma Res; 2015 Aug; 25(4):321-7. PubMed ID: 25933207
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.
Ascierto PA; Del Vecchio M; Robert C; Mackiewicz A; Chiarion-Sileni V; Arance A; Lebbé C; Bastholt L; Hamid O; Rutkowski P; McNeil C; Garbe C; Loquai C; Dreno B; Thomas L; Grob JJ; Liszkay G; Nyakas M; Gutzmer R; Pikiel J; Grange F; Hoeller C; Ferraresi V; Smylie M; Schadendorf D; Mortier L; Svane IM; Hennicken D; Qureshi A; Maio M
Lancet Oncol; 2017 May; 18(5):611-622. PubMed ID: 28359784
[TBL] [Abstract][Full Text] [Related]
8. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.
Maio M; Grob JJ; Aamdal S; Bondarenko I; Robert C; Thomas L; Garbe C; Chiarion-Sileni V; Testori A; Chen TT; Tschaika M; Wolchok JD
J Clin Oncol; 2015 Apr; 33(10):1191-6. PubMed ID: 25713437
[TBL] [Abstract][Full Text] [Related]
9. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.
Horvat TZ; Adel NG; Dang TO; Momtaz P; Postow MA; Callahan MK; Carvajal RD; Dickson MA; D'Angelo SP; Woo KM; Panageas KS; Wolchok JD; Chapman PB
J Clin Oncol; 2015 Oct; 33(28):3193-8. PubMed ID: 26282644
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
11. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.
Zimmer L; Eigentler TK; Kiecker F; Simon J; Utikal J; Mohr P; Berking C; Kämpgen E; Dippel E; Stadler R; Hauschild A; Fluck M; Terheyden P; Rompel R; Loquai C; Assi Z; Garbe C; Schadendorf D
J Transl Med; 2015 Nov; 13():351. PubMed ID: 26541511
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
Eggermont AM; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Konto C; Hoos A; de Pril V; Gurunath RK; de Schaetzen G; Suciu S; Testori A
Lancet Oncol; 2015 May; 16(5):522-30. PubMed ID: 25840693
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma.
Yamazaki N; Kiyohara Y; Uhara H; Fukushima S; Uchi H; Shibagaki N; Tsutsumida A; Yoshikawa S; Okuyama R; Ito Y; Tokudome T
Cancer Chemother Pharmacol; 2015 Nov; 76(5):997-1004. PubMed ID: 26410424
[TBL] [Abstract][Full Text] [Related]
14. Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma.
Luke JJ; Donahue H; Nishino M; Giobbie-Hurder A; Davis M; Bailey N; Ott PA; Hodi FS
Cancer Immunol Res; 2015 Sep; 3(9):986-91. PubMed ID: 25943535
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
Wolchok JD; Neyns B; Linette G; Negrier S; Lutzky J; Thomas L; Waterfield W; Schadendorf D; Smylie M; Guthrie T; Grob JJ; Chesney J; Chin K; Chen K; Hoos A; O'Day SJ; Lebbé C
Lancet Oncol; 2010 Feb; 11(2):155-64. PubMed ID: 20004617
[TBL] [Abstract][Full Text] [Related]
16. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial.
Weber JS; Amin A; Minor D; Siegel J; Berman D; O'Day SJ
Melanoma Res; 2011 Dec; 21(6):530-4. PubMed ID: 22051508
[TBL] [Abstract][Full Text] [Related]
17. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Robert C; Thomas L; Bondarenko I; O'Day S; Weber J; Garbe C; Lebbe C; Baurain JF; Testori A; Grob JJ; Davidson N; Richards J; Maio M; Hauschild A; Miller WH; Gascon P; Lotem M; Harmankaya K; Ibrahim R; Francis S; Chen TT; Humphrey R; Hoos A; Wolchok JD
N Engl J Med; 2011 Jun; 364(26):2517-26. PubMed ID: 21639810
[TBL] [Abstract][Full Text] [Related]
19. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
Chesney J; Puzanov I; Collichio F; Singh P; Milhem MM; Glaspy J; Hamid O; Ross M; Friedlander P; Garbe C; Logan TF; Hauschild A; Lebbé C; Chen L; Kim JJ; Gansert J; Andtbacka RHI; Kaufman HL
J Clin Oncol; 2018 Jun; 36(17):1658-1667. PubMed ID: 28981385
[TBL] [Abstract][Full Text] [Related]
20. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
Sznol M; Ferrucci PF; Hogg D; Atkins MB; Wolter P; Guidoboni M; Lebbé C; Kirkwood JM; Schachter J; Daniels GA; Hassel J; Cebon J; Gerritsen W; Atkinson V; Thomas L; McCaffrey J; Power D; Walker D; Bhore R; Jiang J; Hodi FS; Wolchok JD
J Clin Oncol; 2017 Dec; 35(34):3815-3822. PubMed ID: 28915085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
